A meta-analysis on the association between PPAR-? Pro12Ala polymorphism and polycystic ovary syndrome

Journal of Assisted Reproduction and Genetics

Volumn 29, Issue 7, 2012, Pages 669-677

  He, Junli ^a   Wang, Li ^a   Liu, Junhong ^a   Liu, Feng ^a   Li, Xuliang ^a  

^a CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Body mass index; Fast insulin; Insulin sensitivity; Metaanalysis; Polycystic ovary syndrome; PPAR ?

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; BODY MASS; CONFIDENCE INTERVAL; DATA BASE; DATA EXTRACTION; DNA POLYMORPHISM; EMBASE; GENE; GENETIC ASSOCIATION; GENOTYPE; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MEDLINE; META ANALYSIS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PRO12ALA GENE; RISK; STATISTICAL ANALYSIS;

BODY MASS INDEX; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INSULIN; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA;

EID: 84864945697     PISSN: 10580468     EISSN: 15737330     Source Type: Journal    
DOI: 10.1007/s10815-012-9772-4     Document Type: Article

References (47)

1. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:671-83.
2. Hart R, Norman R. Polycystic ovarian syndrome-prognosis and outcomes. Best Pract Res Clin Obstet Gynaecol. 2006;20:751-78.
3. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond). 2008;32:1035-41.
4. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853-61.
5. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-36.
6. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006;29:278-85. discussion 86-90.
7. Legro RS, Driscoll D, Strauss 3rd JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998;95:14956-60.
8. Battaglia C, Regnani G, Mancini F, Iughetti L, Flamigni C, Venturoli S. Polycystic ovaries in childhood: a common finding in daughters of PCOS patients. A pilot study. Hum Reprod. 2002;17:771-6.
9. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91:2100-4.
10. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia. 1999;42:1033-49.
11. Jansen E, Laven JS, Dommerholt HB, Polman J, van Rijt C, van den Hurk C, et al. Abnormal gene expression profiles in human ovaries from polycystic ovary syndrome patients. Mol Endocrinol. 2004;18:3050-63.
12. Komar CM. Peroxisome proliferator-activated receptors (PPARs) and ovarian function-implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol. 2005;3:41.
13. Lovekamp-Swan T, Chaffin CL. The peroxisome proliferatoractivated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells. Mol Cell Endocrinol. 2005;233:15-24.
14. Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P. Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol. 2006;189:199-209.
15. Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.0.2. The Cochrane Collaboration: 2009. Available from http://www.cochrane-handbook.org.
16. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-6.
17. Higgins J, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat med. 2002;21:1539-58.
18. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab. 2002;87:772-5.
19. Korhonen S, Heinonen S, Hiltunen M, Helisalmi S, Hippelainen M, Koivunen R, et al. Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum Reprod. 2003;18:540-3.
20. Orio Jr F, Matarese G, Di Biase S, Palomba S, Labella D, Sanna V, et al. Exon 6 and 2 peroxisome proliferator-activated receptorgamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:5887-92.
21. San-Millán JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab. 2004;89:2640-6.
22. Orio Jr F, Palomba S, Cascella T, Di Biase S, Labella D, Russo T, et al. Lack of an association between peroxisome proliferatoractivated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:5110-5.
23. Tok EC, Aktas A, Ertunc D, Erdal EM, Dilek S. Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala genotype. Hum Reprod. 2005;20:1590-5.
24. Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B, et al. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2005;62:573-9.
25. Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, et al. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2005;113:275-81.
26. Yilmaz M, ErgunMA, Karakoc A, Yurtcu E, Yetkin I, Ayvaz G, et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome. Gynecol Endocrinol. 2005;21:206-10.
27. Wang Y, Wu X, Cao Y, Yi L, Fan H, Chen J. Polymorphisms of the peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha genes in Chinese women with polycystic ovary syndrome. Fertil Steril. 2006;85:1536-40.
28. Yilmaz M, Ergun MA, Karakoc A, Yurtcu E, Cakir N, Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:336-42.
29. Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R, Goodarzi MO. Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil Steril. 2007;87:862-9.
30. Knebel B, Janssen OE, Hahn S, Jacob S, Gleich J, Kotzka J, et al. Increased low grade inflammatory serum markers in patients with Polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp Clin EndocrinolDiabetes. 2008;116:481-6.
31. Koika V, Marioli DJ, Saltamavros AD, Vervita V, Koufogiannis KD, Adonakis G, et al. Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 with decreased basic metabolic rate in women with polycystic ovary syndrome. Eur J Endocrinol. 2009;161:317-22.
32. Gu BH, Baek KH. Pro12Ala and His447His polymorphisms of PPAR-gamma are associated with polycystic ovary syndrome. Reprod Biomed Online. 2009;18:644-50.
33. Xita N, Lazaros L, Georgiou I, Tsatsoulis A. The Pro12Ala polymorphism of the PPAR-gamma gene is not associated with the polycystic ovary syndrome. Hormones (Athens). 2009;8:267-72.
34. San-Millán JL, Escobar-Morreale HF. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence. Clin Endocrinol (Oxf). 2010;72:383-92.
35. Chae SJ, Kim JJ, Choi YM, Kim JM, Cho YM, Moon SY. Peroxisome proliferator-activated receptor-gamma and its coactivator- 1alpha gene polymorphisms in Korean women with polycystic ovary syndrome. Gynecol Obstet Invest. 2010;70:1-7.
36. Christopoulos P, Mastorakos G, GazouliM, Deligeoroglou E, Katsikis I, Diamanti-Kandarakis E, et al. Peroxisome proliferator-activated receptor-gamma and -delta polymorphisms in women with polycystic ovary syndrome. Ann N YAcad Sci. 2010;1205:185-91.
37. Bidzi?ska-Speichert B, Lenarcik A, Tworowska-Bardzinska U, Slezak R, Bednarek-Tupikowska G, Milewicz A, et al. Pro12Ala PPAR gamma2 gene polymorphism in women with polycystic ovary syndrome. Ginekol Pol. 2011;82:426-9.
38. Bidzi?ska-Speichert B, Lenarcik A, Tworowska-Bardzinska U, Slezak R, Bednarek-Tupikowska G, Milewicz A. Pro12Ala PPAR gamma2 gene polymorphism in PCOS women: the role of compounds regulating satiety. Gynecol Endocrinol. 2012;28:195-8.
39. Dragojevi? J, Marc J, Mlinar B. Association between Pro12Ala and His477His polymorphisms in PPARG gene and insulin resistance in patients with polycystic ovary syndrome. Biochemia Medica. 2008;18:342-50.
40. Nardo LG, Patchava S, Laing I. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. Panminerva Med. 2008;50:267-78.
41. Tonjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care. 2006;29:2489-97
42. Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet. 2003;40:773-80.
43. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284-7.
44. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf). 2002;57:343-50.
45. Palep-Singh M, Picton HM, Vrotsou K, Maruthini D, Balen AH. South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts. Eur J Obstet Gynecol Reprod Biol. 2007;134:202-7.
46. Palep-Singh M, Picton HM, Yates ZR, Barth J, Balen AH. Polycystic ovary syndrome and the single nucleotide polymorphisms of methylenetetrahydrofolate reductase: a pilot observational study. Hum Fertil (Camb). 2007;10:33-41.
47. Glintborg D, Mumm H, Hougaard D, Ravn P, Andersen M. Ethnic differences in Rotterdam criteria and metabolic risk factors in a multiethnic group of women with PCOS studied in Denmark. Clin Endocrinol (Oxf). 2010;73:732-8.